To download the latest issue
May 17th, 2011
Fluidigm introduces fast 192.24 dynamic array™ IFC for genotyping
Fluidigm Corporation (NASDAQ:FLDM) introduced its 192.24 Dynamic Array™ IFC, designed to genotype 192 samples against 24 SNP assays in a single run, providing 4,608 data points in just one hour.
The 192.24 integrated fluidic circuit (IFC) has immediate applicability in agricultural biotechnology and genome wide association studies.
This accelerated workflow and increased throughput enables more data points, while the 192.24 chip retains Fluidigm’s 99.75 percent or greater call accuracy and 99 percent or greater call rates. The new chip can be read using either the BioMark™ HD or EP1™ Systems.
“The Fluidigm 192.24 Dynamic Array chip enables life science researchers to achieve ultra-low cost, and rapid throughput while maintaining full assay and reagent flexibility. Providing the ability to use fewer SNP assays, and run a high number of samples is a format that is ideal for some applications in Ag-Bio and for GWAS follow-up studies,” said Gajus Worthington, Fluidigm president and chief executive officer.
The 192.24 is particularly suited to take advantage of Fluidigm’s new SNPtype™ Assays for genotyping. While the 192.24 Dynamic Array chip will support all industry-standard assays, SNPtype Assays offer a low-cost SNP genotyping solution, are made on-demand, and are ready to meet high-throughput needs for a wide range of agricultural applications and confirmation of next-generation sequencing results.
Fluidigm IFCs, including the 192.24 chip, use just microliters of materials, allowing scientists to achieve comprehensive genetic profiling from miniscule amounts of sample. Each reaction chamber in the 192.24 chip requires only eight nanoliters of material. In addition, all Fluidigm Dynamic Array IFCs feature a matrix-style architecture that automatically assembles every possible reaction between the samples and the assays providing up to 99 percent fewer pipetting steps than needed when using 384-well plates.
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits, or chips, and reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems including nine different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.
More MEDTECH TECHNO news